Key facts
- This page summarizes Jeffrey Lawrence Schwartz's Form 4 filing for SpringWorks Therapeutics, Inc. (SWTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 May 2023, 17:04.
Jeffrey Lawrence Schwartz - 24 May 2023 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)
- Reporting relationship
- Director
- Issuer ticker
- SWTX
- Reported as of
- 24 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 May 2023, 17:04:48 UTC
- Prior SEC filing
- 05 May 2023
- Next SEC filing
- 28 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Schwartz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Lawrence Schwartz filed Form 4 for SpringWorks Therapeutics, Inc. (SWTX) on 25 May 2023.
Change
- Previous filing in this sequence was filed on 05 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SWTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,648
- Change %
- +78%
- Price
- $0.000000
- Shares after
- 10,572
- Date
- 24 May 2023
- Ownership
- Direct
- Footnotes
- F1
SWTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,081,307
- Date
- 24 May 2023
- Ownership
- See footnote
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SWTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,774
- Change %
- Price
- $0.000000
- Shares after
- 13,774
- Date
- 24 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,774
- Exercise price
- $32.27
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
Footnote F2
This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.
Footnote F3
The options shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
Footnote F4
Represents shares of common stock held directly by BC SW, LP. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of BC SW, LP. The Reporting Person is a Partner of BCLSI. As a result, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC SW, LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.